Tuesday, September 25, 2012

Google Inc (NASDAQ:GOOG) is the stock which has been
consistently making new highs and today once again the stock hit a record high
of $764.89. Yesterday, the stock was up over 2% as investors as well as
investors community have turned bullish on the company’s ad model. Analysts are
bullish on the company’s business and estimate that the company to be
increasingly attractive when compared to a new group of social web companies. An
analyst at Pivotal Research Group, Brian Wieser said that the markets have come
to appreciate Google’s efforts in making money.

Last week, eMarketer had issued
a research note stating that Google Inc(NASDAQ:GOOG) will topple Facebook
Inc(NASDAQ:FB) from the top position of display ads this year. According to the
research firm, Google is all set out to branch out and increase its revenue from
advertisements, and by dominating the arena of display ads, it will lead as the
organization with three kinds of advertising. Namely, Search, mobile, and
display.

In other news, Eric Schmidt, CEO of Google Inc
(NASDAQ:GOOG) has said
that the firm will need Apple Inc.(NASDAQ:AAPL)’s approval to offer its mapping
application for the iPhones. This happened after the software was replaced with
an Apple’s mapping program that has faced a number of criticisms.

Exxon Mobil Corporation(NYSE:XOM) is another stock
which is hitting multi year high in today’s session and rose 0.08% to $91.95
after creating a new highs at $92.57.

ExxonMobil, in its exploration venture with Russia’s
Rosneft in the Kara Sea will be drilling into the arctic seabed near the where
the Soviet navy dumped old nuclear reactors, 17,000 loads of radioactive waste
and even scuttled a nuclear-powered submarine.

Pfizer Inc.(NYSE:PFE) made multi year high of $25.15
this morning and was recently up 1% at $25. Recently, A U.S. District Judge has
granted class-action status to former Wyeth investors who accused the Pfizer unit
of misleading them about risks associated with its antidepressant drug Pristiq.
The FDA rejected the drug in July, 2007 over potential serious heart and liver
problems associated with its use. A Pfizer spokesperson says the company will
continue to defend itself vigorously.